Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging

Blood (2025) 146 (22): 2681–2695.

https://doi.org/10.1182/blood.2024027692

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy of low-dose rituximab as preemptive treatment of EBV-DNA-emia after allogeneic hematopoietic stem cell transplantation

Yi Wang, Yaoyao Shen, Ying Wang, Depei Wu

Blood (2025) 146 (Supplement 1): 2504.

https://doi.org/10.1182/blood-2025-2504

Published: 2025

Journal Articles

Impact of slim-CRAB criteria on treatment initiation in newly diagnosed multiple myeloma in the veteran health administration

Mengmeng Ji, Mahta Salehi, Mei Wang, John Huber, Rong Wang, Shi-Yi Wang, Martin Schoen, Su-Hsin Chang

Blood (2025) 146 (Supplement 1): 6378.

https://doi.org/10.1182/blood-2025-6378

Published: 2025

Journal Articles

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Blood (2025) 146 (Supplement 1): 843.

https://doi.org/10.1182/blood-2025-843

Published: 2025

Journal Articles

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

Wei LIU, Yan Xu, Yi Wang, Weiwei Sui, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2025-3720

Published: 2025

Journal Articles

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Huixing Zhou, Chunrui Li, Baijun Fang, Lingzhi Yan, Aijun Liu, Peiling Zhang, Yang Liu, Xiaoqi Qin, Huanxin Zhang, Wei Zhou, Hong-Hu Zhu, Leng Yun, Yin WU, Yi Wang, Wenming Chen, Guangzhong Yang

Blood (2025) 146 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2025-2271

Published: 2025

Journal Articles

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Huanxin Zhang, Yi Wang, Chengcheng Fu, Yanli Feng, Yang Liu, Jing Wang, Chunrui Li, Wenming Chen, Zhenyu Li

Blood (2025) 146 (Supplement 1): 2270.

https://doi.org/10.1182/blood-2025-2270

Published: 2025

Journal Articles

Efficacy and safety of aponermin combined with immunomodulators in relapsed/refractory multiple myeloma

Xiujuan Huang, Yanping Ma, Zhenyu Li, Juan Li, Yuzhang Liu, Yaomei Wang, Chao Song, Xiaoqi Qin, Wenming Chen, Yi Wang

Blood (2025) 146 (Supplement 1): 7571.

https://doi.org/10.1182/blood-2025-7571

Published: 2025

Journal Articles

Efficacy and safety analysis of iptacopan in paroxysmal nocturnal hemoglobinuria: A real world retrospective study of China

Yi Wang, Yanli Feng, Chao Song, Ben Niu, Yuting Yang, Limin Hou

Blood (2025) 146 (Supplement 1): 1103.

https://doi.org/10.1182/blood-2025-1103

Published: 2025

Journal Articles

The exercise-induced myokine irisin acts as an endogenous anti-thrombotic agent by modulating multiple target cells

Martha Sim, Daniel Gao, Jennie Le, Jeffrey Harris, Xiaohong Wang, Yi Wang, Xiaoyun Fu, Junmei Chen, Reheman Adili, José López

Blood (2025) 146 (Supplement 1): 425.

https://doi.org/10.1182/blood-2025-425

Published: 2025

Journal Articles

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Wei LIU, Yi Wang, Huimin Liu, Qi Wang, Hesong Zou, Yan Xu, Wenyang Huang, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 3683.

https://doi.org/10.1182/blood-2025-3683

Published: 2025

Journal Articles

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Hesong Zou, Chen Jia, Wei LIU, Huimin Liu, Yi Wang, Yan Xu, Shuhua Yi, Gang An, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2025-1938

Published: 2025

Journal Articles

Impact of slim-CRAB criteria on diagnostic practices among patients with MGUS in the veteran health administration

Mengmeng Ji, Mahta Salehi, Mei Wang, John Huber, Rong Wang, Shi-Yi Wang, Martin Schoen, Su-Hsin Chang

Blood (2025) 146 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2025-3972

Published: 2025

Journal Articles

Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia

Yi Wang, Ling Li, Shijia Li, Yanli Feng, Tongxia Lu, Aaron Lobo

Blood (2025) 146 (Supplement 1): 6976.

https://doi.org/10.1182/blood-2025-6976

Published: 2025

Journal Articles

Low-dose chemotherapy for induction in pediatric AML: Retrospective outcome analysis across expanded cohorts

Blood (2025) 146 (Supplement 1): 1661.

https://doi.org/10.1182/blood-2025-1661

Published: 2025

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Blood (2025) 146 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2025-3889

Published: 2025

Journal Articles

Multicenter prospective Phase II study of decitabine priming combined with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5233.

https://doi.org/10.1182/blood-2025-5233

Published: 2025

Journal Articles

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5666.

https://doi.org/10.1182/blood-2025-5666

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging

Efficacy of low-dose rituximab as preemptive treatment of EBV-DNA-emia after allogeneic hematopoietic stem cell transplantation

Impact of slim-CRAB criteria on treatment initiation in newly diagnosed multiple myeloma in the veteran health administration

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Efficacy and safety of aponermin combined with immunomodulators in relapsed/refractory multiple myeloma

Efficacy and safety analysis of iptacopan in paroxysmal nocturnal hemoglobinuria: A real world retrospective study of China

The exercise-induced myokine irisin acts as an endogenous anti-thrombotic agent by modulating multiple target cells

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Impact of slim-CRAB criteria on diagnostic practices among patients with MGUS in the veteran health administration

Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia

Low-dose chemotherapy for induction in pediatric AML: Retrospective outcome analysis across expanded cohorts

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Multicenter prospective Phase II study of decitabine priming combined with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed Acute Myeloid Leukemia

Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only